Immunocore Holdings PLC（IMCR）财务数据IMCRImmunocore Holdings PLC

Immunocore Holdings PLC (IMCR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product revenue, accounting for 96.6% of total sales, equivalent to $62.91M. Another important revenue stream is Genentech. Understanding this composition is critical for investors evaluating how IMCR navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Immunocore Holdings PLC maintains a gross margin of 99.06%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2.58%, while the net margin is -0.70%. These profitability ratios, combined with a Return on Equity (ROE) of -4.47%, provide a clear picture of how effectively IMCR converts its operational activities into shareholder value.

In the context of the broader market, IMCR competes directly with industry leaders such as GENB and NVAX. With a market capitalization of $1.60B, it holds a significant position in the sector. When comparing efficiency, IMCR's gross margin of 99.06% stands against GENB's 100.00% and NVAX's 78.93%. Such benchmarking helps identify whether Immunocore Holdings PLC is trading at a premium or discount relative to its financial performance.

Immunocore's revenue for Q2 2026 was $116 million, with a net income of $12.97 million, reflecting improved execution despite some revenue shortfalls. The gross margin remains strong at 99.06%, indicating effective cost management.